BW Gestao de Investimentos Ltda. Has $14.51 Million Stake in Clarivate PLC $CLVT

BW Gestao de Investimentos Ltda. boosted its position in shares of Clarivate PLC (NYSE:CLVT) by 51.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 4,345,321 shares of the company’s stock after purchasing an additional 1,480,300 shares during the period. BW Gestao de Investimentos Ltda.’s holdings in Clarivate were worth $14,513,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in CLVT. M&T Bank Corp acquired a new stake in shares of Clarivate in the 4th quarter valued at approximately $34,000. Essex Financial Services Inc. acquired a new stake in shares of Clarivate in the 3rd quarter valued at approximately $41,000. North Dakota State Investment Board acquired a new stake in shares of Clarivate in the 4th quarter valued at approximately $42,000. Beese Fulmer Investment Management Inc. acquired a new stake in shares of Clarivate in the 4th quarter valued at approximately $44,000. Finally, PharVision Advisers LLC acquired a new stake in shares of Clarivate in the 3rd quarter valued at approximately $45,000. 85.72% of the stock is currently owned by institutional investors and hedge funds.

Clarivate Stock Performance

NYSE:CLVT opened at $2.73 on Tuesday. The company has a fifty day moving average of $2.53 and a 200-day moving average of $2.80. The firm has a market capitalization of $1.74 billion, a P/E ratio of -12.98 and a beta of 1.37. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 0.89. Clarivate PLC has a twelve month low of $1.66 and a twelve month high of $4.77.

Clarivate (NYSE:CLVT) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.04. The firm had revenue of $585.50 million for the quarter, compared to the consensus estimate of $569.50 million. Clarivate had a negative net margin of 5.61% and a positive return on equity of 8.82%. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.14 EPS. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. As a group, sell-side analysts anticipate that Clarivate PLC will post 0.65 EPS for the current year.

Analyst Ratings Changes

Several research firms recently commented on CLVT. Barclays cut their target price on shares of Clarivate from $4.00 to $2.40 and set an “underweight” rating on the stock in a research report on Wednesday, February 25th. Royal Bank Of Canada cut their target price on shares of Clarivate from $5.00 to $3.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 25th. Wall Street Zen upgraded shares of Clarivate from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Citigroup cut their target price on shares of Clarivate from $4.25 to $2.80 and set a “neutral” rating on the stock in a research report on Wednesday, March 4th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Clarivate in a report on Friday, March 27th. Five analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Clarivate has an average rating of “Reduce” and a consensus price target of $3.22.

Clarivate Company Profile

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.